Pfizer Inc
NYSE:PFE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pfizer Inc
Cash & Cash Equivalents
Pfizer Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Pfizer Inc
NYSE:PFE
|
Cash & Cash Equivalents
$1.1B
|
CAGR 3-Years
40%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-11%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash & Cash Equivalents
$9.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
16%
|
CAGR 10-Years
-4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash & Cash Equivalents
$10.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
16%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash & Cash Equivalents
$14.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
16%
|
CAGR 10-Years
4%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Cash & Cash Equivalents
$2.3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash & Cash Equivalents
$5.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
Pfizer Inc
Glance View
Pfizer Inc., a name synonymous with pharmaceutical innovation, embarked on its journey in 1849 when German immigrants Charles Pfizer and Charles Erhart founded the company in Brooklyn, New York. Over the decades, the modest chemical business transformed into a titan of the pharmaceutical industry, delivering breakthroughs that have shaped modern medicine. The company operates through its robust engine of research and development, continually investing billions into discovering and bringing to market medications that address unmet medical needs. Spanning therapeutic areas such as oncology, vaccines, rare diseases, and cardiovascular and metabolic health, Pfizer's strategic focus ensures a diverse product pipeline that aligns with global health trends and challenges. The company's revenue model is predominantly driven by the development, marketing, and sale of its pharmaceutical products. Blockbuster drugs like Lipitor and recently, the COVID-19 vaccine developed in collaboration with BioNTech, have contributed significantly to its earnings. Pfizer's ability to maintain a strong balance between branded pharmaceuticals and generics allows it to effectively cater to both emerging markets and developed economies, while its strategic partnerships and acquisitions further bolster its reach and capabilities. The synergy of science and business acumen at Pfizer has made it not only a hub of medical innovation but also a formidable enterprise in the competitive landscape of healthcare.
See Also
What is Pfizer Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.1B
USD
Based on the financial report for Dec 31, 2025, Pfizer Inc's Cash & Cash Equivalents amounts to 1.1B USD.
What is Pfizer Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-11%
Over the last year, the Cash & Cash Equivalents growth was 9%. The average annual Cash & Cash Equivalents growth rates for Pfizer Inc have been 40% over the past three years , -9% over the past five years , and -11% over the past ten years .